Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 527
Filtrar
1.
Waste Manag ; 118: 313-322, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-32919350

RESUMO

Life cycle assessment (LCA) has been used in waste management for the last two decades and hundreds of journal papers have been published. The use of LCA in waste management has provided a much-improved holistic view of waste management including waste flows and potential environmental impacts. Although much knowledge has been obtained from LCA studies, there is still a need to use LCA models in integrated waste management. This paper describes six areas where LCA is expected to play a role in waste management in the future: 1) understanding an existing waste management system; 2) improving existing waste management systems; 3) comparing alternative technologies/ technology performance; 4) technology development/prospective technologies; 5) policy development/strategic development; and 6) reporting. Illustrative examples are provided for each application area.


Assuntos
Eliminação de Resíduos , Gerenciamento de Resíduos , Meio Ambiente , Formulação de Políticas , Estudos Prospectivos
2.
J Mol Endocrinol ; 62(4): 159-168, 2019 05 01.
Artigo em Inglês | MEDLINE | ID: mdl-30917339

RESUMO

Modified lipoproteins can negatively affect beta cell function and survival. However, the mechanisms behind interactions of modified lipoproteins with beta cells - and in particular, relationships to increased uptake - are only partly clarified. By over-expressing the scavenger receptor CD36 (Tet-on), we increased the uptake of fluorescent low-density modified lipoprotein (oxLDL) into insulin-secreting INS-1 cells. The magnitude of uptake followed the degree of CD36 over-expression. CD36 over-expression increased concomitant efflux of 3H-cholesterol in proportion to the cellular contents of 3H-cholesterol. Exposure to concentrations of oxLDL from 20 to 100 µg/mL dose-dependently increased toxicity (evaluated by MTT) as well as apoptosis. However, the increased uptake of oxLDL due to CD36 over-expression did not exert additive effects on oxLDL toxicity - neither on viability, nor on glucose-induced insulin release and cellular content. Reciprocally, blocking CD36 receptors by Sulfo-N-Succinimidyl Oleate decreased the uptake of oxLDL but did not diminish the toxicity. Pancreatic islets of CD36-/- mice displayed reduced uptake of 3H-cholesterol-labeled oxLDL vs wild type but similar toxicity to oxLDL. OxLDL was found to increase the expression of CD36 in islets and INS-1 cells. In summary, given the experimental conditions, our results indicate that (1) increased uptake of oxLDL is not responsible for toxicity of oxLDL, (2) increased efflux of the cholesterol moiety of oxLDL counterbalances, at least in part, increased uptake and (3) oxLDL participates in the regulation of CD36 in pancreatic islets and in INS-1 cells.


Assuntos
Células Secretoras de Insulina/metabolismo , Lipoproteínas LDL/metabolismo , Animais , Transporte Biológico/efeitos dos fármacos , Transporte Biológico/fisiologia , Antígenos CD36/genética , Antígenos CD36/metabolismo , Sobrevivência Celular/efeitos dos fármacos , Sobrevivência Celular/fisiologia , Colesterol/metabolismo , Doxiciclina/farmacologia , Citometria de Fluxo , Insulina/metabolismo , Células Secretoras de Insulina/efeitos dos fármacos , Lipoproteínas LDL/farmacologia , Masculino , Camundongos , Microscopia Confocal , Ratos , Reação em Cadeia da Polimerase em Tempo Real
3.
Transfusion ; 58(6): 1442-1451, 2018 06.
Artigo em Inglês | MEDLINE | ID: mdl-29536557

RESUMO

BACKGROUND: The composition of the graft used for allogeneic hematopoietic stem cell transplantation (HSCT) is important for the treatment outcome. Different apheresis devices may yield significant differences in peripheral blood stem cell graft cellular composition. We compared stem cell grafts produced by Cobe Spectra (Cobe) and Spectra Optia (Optia) with use of the mononuclear cell (MNC) protocol, and evaluated clinical outcome parameters such as graft-versus-host disease (GvHD), transplant-related mortality (TRM), relapse, and overall survival. STUDY DESIGN AND METHODS: During 5 years, 31 Cobe Spectra and 40 Spectra Optia grafts were analyzed for CD34, CD3, CD4, CD8, CD19, and CD56 cell content. Clinical outcome parameters were correlated and compared between the two patient groups using different apheresis devices. RESULTS: Optia grafts contained fewer lymphocytes compared to Cobe (p < 0.001). Optia grafts had a significantly lower incidence of acute GvHD Grades II through IV (Cobe 45% vs. Optia 23%; p = 0.039) and TRM (16% vs. 2.5%; p < 0.05) but higher chronic GvHD (32% vs. 67%; p = 0.005) compared to Cobe grafts. Finally, the multivariate analysis showed a significant correlation among the different apheresis devices and both acute GvHD II through IV and severe chronic GvHD. The multivariate analysis also showed a significant correlation between the CD3+ cell dose and the incidence of severe acute GvHD. CONCLUSION: Optia-obtained grafts yielded a lower acute GvHD Grades II-IV and TRM risk, but had no impact on relapse or overall survival in this study. Understanding and further improvement of peripheral blood stem cell (PBSC) apheresis techniques may be used in the future to personalize HSCT by, for example, fine-tuning the GvHD incidence.


Assuntos
Remoção de Componentes Sanguíneos/instrumentação , Doença Enxerto-Hospedeiro/etiologia , Doadores de Tecidos , Transplante Homólogo/efeitos adversos , Doença Aguda , Adulto , Antígenos CD/sangue , Remoção de Componentes Sanguíneos/normas , Complexo CD3/sangue , Feminino , Doença Enxerto-Hospedeiro/mortalidade , Humanos , Incidência , Contagem de Linfócitos , Masculino , Pessoa de Meia-Idade , Transplante de Células-Tronco de Sangue Periférico/efeitos adversos , Transplante de Células-Tronco de Sangue Periférico/métodos , Transplante de Células-Tronco de Sangue Periférico/mortalidade , Recidiva , Análise de Sobrevida , Transplante Homólogo/mortalidade
7.
Behav Brain Res ; 296: 129-133, 2016 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-26341317

RESUMO

Parkinson's disease (PD) is associated with extensive degeneration of dopaminergic neurons originating in the substantia nigra pars compacta, but neuronal loss is also found in the ventral tegmental area (VTA). The VTA projects to areas involved in cognitive and emotional processes, including hippocampus, amygdala, nucleus accumbens and prefrontal cortex, and has thus been proposed to play a role in emotional memory impairments in PD. Since the formation of α-synuclein inclusions throughout the central nervous system is a pathological hallmark of PD, we studied the progressive effects of α-synuclein overexpression in the VTA on motor functions, emotional behaviour and emotional memory. Adeno-associated viral (AAV) vectors encoding either human α-synuclein or green fluorescent protein (GFP) were injected stereotactically into the VTA, and behaviour was monitored 3 and 8 weeks following AAV injection. At week 8, there was a 22% reduction of TH+ neurons in the VTA. We demonstrate that α-synuclein overexpression in dopaminergic neurons of the VTA induced mild motor deficits that appeared 3 weeks following AAV-α-synuclein injection and were aggravated at week 8. No depressive- or anxiety-like behaviours were found. To address emotional memory, we used the passive avoidance test, a one-trial associative learning paradigm based on contextual conditioning which requires minimal training. Interestingly, emotional memory impairments were found in α-synuclein overexpressing animals at week 8. These findings indicate that α-synuclein overexpression induces progressive memory impairments likely caused by a loss of function of mesolimbic dopaminergic projections.


Assuntos
Neurônios Dopaminérgicos/metabolismo , Emoções/fisiologia , Transtornos da Memória/metabolismo , Área Tegmentar Ventral/metabolismo , alfa-Sinucleína/metabolismo , Animais , Aprendizagem por Associação/fisiologia , Comportamento Animal/fisiologia , Dependovirus , Feminino , Vetores Genéticos , Proteínas de Fluorescência Verde , Humanos , Ratos Sprague-Dawley , alfa-Sinucleína/administração & dosagem
8.
Acta Paediatr ; 105(6): 676-83, 2016 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-26355275

RESUMO

AIM: The aim of this study was to coordinate the structured psychosocial, neurocognitive and educational follow-up of children treated for brain tumours with the medical protocol and apply the model in two Swedish healthcare regions. METHODS: We invited all children living in the two regions, who had been diagnosed with a brain tumour from October 1, 2010, through June 30, 2012, to participate along with their parents. The follow-up programme evaluated the emotional status of the parents and patients and assessed the children's general cognitive level, working memory, speed of performance, executive functions and academic achievement from diagnosis through to adult care. RESULTS: During the study period, 61 children up to the age of 17.1 years were diagnosed with a brain tumour, but 18 of these were excluded for various reasons. The majority of the mothers (70%) displayed significantly poor emotional status, as did 34% of the fathers and 21% of the children. The majority of the children (57%) also showed poor neurocognitive performance and needed special adaptations at school (66%). CONCLUSION: Our findings indicate the need for coordinated, multiprofessional follow-up programmes, well anchored in the healthcare organisation, for children diagnosed with brain tumours.


Assuntos
Neoplasias Encefálicas/reabilitação , Adolescente , Neoplasias Encefálicas/psicologia , Criança , Pré-Escolar , Cognição , Avaliação Educacional , Feminino , Humanos , Lactente , Masculino , Pais/psicologia , Estudos Prospectivos
9.
Exp Neurol ; 273: 243-52, 2015 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-26363495

RESUMO

Parkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive loss of nigral dopaminergic neurons and by the presence of aggregates containing α-synuclein called Lewy bodies. Viral vector-induced overexpression of α-synuclein in dopaminergic neurons represents a model of PD which recapitulates disease progression better than commonly used neurotoxin models. Previous studies using this model have reported motor and cognitive impairments, whereas depression, mood and anxiety phenotypes are less described. To investigate these psychiatric phenotypes, Sprague-Dawley rats received bilateral injections of a recombinant adeno-associated virus (AAV) vector expressing human α-synuclein or GFP into the substantia nigra pars compacta. Behavior was assessed at two timepoints: 3 and 8 weeks post-injection. We report that nigral α-synuclein overexpression led to a pronounced nigral dopaminergic cell loss accompanied by a smaller cell loss in the ventral tegmental area, and to a decreased striatal density of dopaminergic fibers. The AAV-α-synuclein group exhibited modest, but significant motor impairments 8 weeks after vector administration. The AAV-α-synuclein group displayed depressive-like behavior in the forced swim test after 3 weeks, and reduced sucrose preference at week 8. At both timepoints, overexpression of α-synuclein was linked to a hyperactive hypothalamic-pituitary-adrenal (HPA) axis regulation of corticosterone. The depressive-like phenotype was also correlated with decreased nigral brain-derived neurotrophic factor and spinophilin levels, and with decreased striatal levels of the activity-regulated cytoskeleton-associated protein. This study demonstrates that AAV-mediated α-synuclein overexpression in dopamine neurons is not only useful to model motor impairments of PD, but also depression. This study also provides evidence that depression in experimental Parkinsonism is correlated to dysregulation of the HPA axis and to alterations in proteins involved in synaptic plasticity.


Assuntos
Depressão/patologia , Neurônios Dopaminérgicos/patologia , Regulação da Expressão Gênica/genética , Mesencéfalo/patologia , alfa-Sinucleína/metabolismo , Hormônio Adrenocorticotrópico/sangue , Animais , Corticosterona/sangue , Dependovirus/genética , Depressão/sangue , Depressão/etiologia , Depressão/genética , Modelos Animais de Doenças , Feminino , Preferências Alimentares/psicologia , Humanos , Estudos Longitudinais , Aprendizagem em Labirinto/fisiologia , Fenótipo , Desempenho Psicomotor/fisiologia , Ratos , Ratos Sprague-Dawley , Ratos Transgênicos , Estresse Psicológico/complicações , Natação/psicologia , Fatores de Tempo , alfa-Sinucleína/genética
10.
Bone Marrow Transplant ; 50(9): 1217-23, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26030049

RESUMO

Vitamin D has emerged as a central player in the immune system, with its deficiency being implicated in the pathogenesis of several autoimmune diseases, including chronic GvHD. This is a retrospective cohort analysis of 166 patients, who underwent allogeneic hematopoietic stem cell transplantation (HSCT) at the Karolinska University Hospital, evaluating GvHD, graft failure, infectious complications and survival after HSCT in relation to pre-transplantation vitamin D levels. Most of the patients were deficient in vitamin D before HSCT (median 42 nmol/L). In multivariate analysis, vitamin D level before HSCT was identified as a significant independent risk factor for development of cGvHD. The increased incidence of cGvHD was not coupled to better disease-free survival; instead there was a trend towards lower overall survival in the vitamin D-deficient patients. In addition, we found a significant correlation between vitamin D deficiency and incidence of CMV disease, with no case of CMV disease occurring in patients with sufficient levels of vitamin D before HSCT. Our results support a role of vitamin D in immune tolerance following HSCT. These findings could be highly relevant for the care of HSCT patients, and prospective, randomized studies on the effect of vitamin D supplementation are therefore needed.


Assuntos
Infecções por Citomegalovirus/epidemiologia , Citomegalovirus , Doença Enxerto-Hospedeiro/epidemiologia , Transplante de Células-Tronco Hematopoéticas , Neoplasias/terapia , Deficiência de Vitamina D/epidemiologia , Adulto , Aloenxertos , Doença Crônica , Infecções por Citomegalovirus/etiologia , Infecções por Citomegalovirus/terapia , Feminino , Doença Enxerto-Hospedeiro/etiologia , Doença Enxerto-Hospedeiro/terapia , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Neoplasias/epidemiologia , Deficiência de Vitamina D/complicações , Deficiência de Vitamina D/terapia
11.
Cell Death Dis ; 3: e322, 2012 Jun 14.
Artigo em Inglês | MEDLINE | ID: mdl-22695615

RESUMO

The success of pancreatic ß-cells transplantation to treat type 1 diabetes has been hindered by massive ß-cell dysfunction and loss of ß-cells that follows the procedure. Hypoxia-mediated cell death has been considered one of the main difficulties that must be overcome for transplantation to be regarded as a reliable therapy. Here we have investigated the mechanisms underlying ß-cell death in response to hypoxia (1% O(2)). Our studies show that mouse insulinoma cell line 6 (Min6) cells undergo apoptosis with caspase-3 activation occurring as early as 2 h following exposure to hypoxia. Hypoxia induces endoplasmic reticulum stress in Min6 cells leading to activation of the three branches of the unfolded protein response pathway. In response to hypoxia the pro-apoptotic transcription factor C/EBP homologous protein (CHOP) is upregulated. The important role of CHOP in the apoptotic process was highlighted by the rescue of Min6 cells from hypoxia-mediated apoptosis observed in CHOP-knockdown cells. Culturing isolated pancreatic mouse islets at normoxia showed intracellular hypoxia with accumulation of hypoxia-inducible factor-1α and upregulation of CHOP, the latter one occurring as early as 4 h after isolation. Finally, we observed that pancreatic islets of type 2 db/db diabetic mice were more hypoxic than their counterpart in normoglycemic animals. This finding indicates that hypoxia-mediated apoptosis may occur in type 2 diabetes.


Assuntos
Apoptose , Células Secretoras de Insulina/metabolismo , Fator de Transcrição CHOP/genética , Resposta a Proteínas não Dobradas , Regulação para Cima , Animais , Hipóxia Celular , Linhagem Celular Tumoral , Feminino , Insulinoma , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Fator de Transcrição CHOP/metabolismo , Ativação Transcricional
12.
Exp Neurol ; 235(1): 306-15, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22394547

RESUMO

Development of relevant models of Parkinson's disease (PD) is essential for a better understanding of the pathological processes underlying the human disease and for the evaluation of promising targets for therapeutic intervention. To date, most pre-clinical studies have been performed in the well-established rodent and non-human primate models using injection of 6-hydroxydopamine (6-OHDA) or 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine (MPTP). Overexpression of the disease-causing protein α-synuclein (α-syn), using adeno-associated viral (AAV) vectors, has provided a novel model that recapitulates many features of the human disease. In the present study we compared the AAV-α-syn rat model with models where the nigro-striatal pathway is lesioned by injection of 6-OHDA in the striatum (partial lesion) or the medial forebrain bundle (full lesion). Examination of the behavioural changes over time revealed a different progression and magnitude of the motor impairment. Interestingly, dopamine (DA) neuron loss is prominent in both the toxin and the AAV-α-syn models. However, α-syn overexpressing animals were seen to exhibit less cell and terminal loss for an equivalent level of motor abnormalities. Prominent and persistent axonal pathology is only observed in the α-syn rat model. We suggest that, while neuronal and terminal loss mainly accounts for the behavioural impairment in the toxin-based model, similar motor deficits result from the combination of cell death and dysfunction of the remaining nigro-striatal neurons in the AAV-α-syn model. While the two models have been developed to mimic DA neuron deficiency, they differ in their temporal and neuropathological characteristics, and replicate different aspects of the pathophysiology of the human disease. This study suggests that the AAV-α-syn model replicates the human pathology more closely than either of the other two 6-OHDA lesion models.


Assuntos
Comportamento Animal/efeitos dos fármacos , Corpo Estriado/patologia , Modelos Animais de Doenças , Oxidopamina/intoxicação , Doença de Parkinson Secundária/patologia , Doença de Parkinson Secundária/fisiopatologia , Substância Negra/patologia , alfa-Sinucleína/genética , Animais , Comportamento Animal/fisiologia , Corpo Estriado/efeitos dos fármacos , Corpo Estriado/metabolismo , Corpo Estriado/fisiopatologia , Feminino , Feixe Prosencefálico Mediano/metabolismo , Feixe Prosencefálico Mediano/patologia , Feixe Prosencefálico Mediano/fisiopatologia , Atividade Motora/efeitos dos fármacos , Atividade Motora/genética , Degeneração Neural/genética , Degeneração Neural/metabolismo , Degeneração Neural/patologia , Degeneração Neural/fisiopatologia , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Neurônios/patologia , Doença de Parkinson Secundária/genética , Doença de Parkinson Secundária/metabolismo , Ratos , Ratos Sprague-Dawley , Substância Negra/efeitos dos fármacos , Substância Negra/metabolismo , Substância Negra/fisiopatologia , alfa-Sinucleína/metabolismo
13.
Cell Death Dis ; 3: e262, 2012 Jan 26.
Artigo em Inglês | MEDLINE | ID: mdl-22278289

RESUMO

Sorafenib, a multi-tyrosine kinase inhibitor, kills more effectively the non-metastatic prostate cancer cell line 22Rv1 than the highly metastatic prostate cancer cell line PC3. In 22Rv1 cells, constitutively active STAT3 and ERK are targeted by sorafenib, contrasting with PC3 cells, in which these kinases are not active. Notably, overexpression of a constitutively active MEK construct in 22Rv1 cells stimulates the sustained phosphorylation of Bad and protects from sorafenib-induced cell death. In PC3 cells, Src and AKT are constitutively activated and targeted by sorafenib, leading to an increase in Bim protein levels. Overexpression of constitutively active AKT or knockdown of Bim protects PC3 cells from sorafenib-induced killing. In both PC3 and 22Rv1 cells, Mcl-1 depletion is required for the induction of cell death by sorafenib as transient overexpression of Mcl-1 is protective. Interestingly, co-culturing of primary cancer-associated fibroblasts (CAFs) with 22Rv1 or PC3 cells protected the cancer cells from sorafenib-induced cell death, and this protection was largely overcome by co-administration of the Bcl-2 antagonist, ABT737. In summary, the differential tyrosine kinase profile of prostate cancer cells defines the cytotoxic efficacy of sorafenib and this profile is modulated by CAFs to promote resistance. The combination of sorafenib with Bcl-2 antagonists, such as ABT737, may constitute a promising therapeutic strategy against prostate cancer.


Assuntos
Benzenossulfonatos/farmacologia , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Neoplasias da Próstata/genética , Proteínas Proto-Oncogênicas c-bcl-2/genética , Piridinas/farmacologia , Transdução de Sinais/efeitos dos fármacos , Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Apoptose/efeitos dos fármacos , Carcinoma , Linhagem Celular Tumoral , Proliferação de Células , Técnicas de Cocultura , Resistencia a Medicamentos Antineoplásicos/efeitos dos fármacos , Fibroblastos/citologia , Fibroblastos/metabolismo , Humanos , Masculino , Terapia de Alvo Molecular , Proteína de Sequência 1 de Leucemia de Células Mieloides , Niacinamida/análogos & derivados , Compostos de Fenilureia , Fosforilação/efeitos dos fármacos , Cultura Primária de Células , Próstata , Neoplasias da Próstata/tratamento farmacológico , Neoplasias da Próstata/patologia , Inibidores de Proteínas Quinases/farmacologia , Proteínas Proto-Oncogênicas c-akt/genética , Proteínas Proto-Oncogênicas c-akt/metabolismo , Proteínas Proto-Oncogênicas c-bcl-2/antagonistas & inibidores , Proteínas Proto-Oncogênicas c-bcl-2/metabolismo , Proteínas Proto-Oncogênicas pp60(c-src)/genética , Proteínas Proto-Oncogênicas pp60(c-src)/metabolismo , Transdução de Sinais/genética , Sorafenibe
14.
Neurobiol Dis ; 45(3): 939-53, 2012 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22182688

RESUMO

Parkinson's disease (PD) is characterised by the progressive loss of nigral dopamine neurons and the presence of synucleinopathy. Overexpression of α-synuclein in vivo using viral vectors has opened interesting possibilities to model PD-like pathology in rodents. However, the attempts made so far have failed to show a consistent behavioural phenotype and pronounced dopamine neurodegeneration. Using a more efficient adeno-associated viral (AAV) vector construct, which includes a WPRE enhancer element and uses the neuron-specific synapsin-1 promoter to drive the expression of human wild-type α-synuclein, we have now been able to achieve increased levels of α-synuclein in the transduced midbrain dopamine neurons sufficient to induce profound deficits in motor function, accompanied by reduced expression of proteins involved in dopamine neurotransmission and a time-dependent loss of nigral dopamine neurons, that develop progressively over 2-4 months after vector injection. As in human PD, nigral cell loss was preceded by degenerative changes in striatal axons and terminals, and the appearance of α-synuclein positive inclusions in dystrophic axons and dendrites, supporting the idea that α-synuclein-induced pathology hits the axons and terminals first and later progresses to involve also the cell bodies. The time-course of changes seen in the AAV-α-synuclein treated animals defines distinct stages of disease progression that matches the pre-symptomatic, early symptomatic, and advanced stages seen in PD patients. This model provides new interesting possibilities for studies of stage-specific pathologic mechanisms and identification of targets for disease-modifying therapeutic interventions linked to early or late stages of the disease.


Assuntos
Sintomas Comportamentais/genética , Neurônios Dopaminérgicos/metabolismo , Vetores Genéticos/fisiologia , Mesencéfalo/patologia , Doenças Neurodegenerativas/genética , alfa-Sinucleína/genética , Anfetamina/farmacologia , Análise de Variância , Animais , Antiparkinsonianos/farmacologia , Antiparkinsonianos/uso terapêutico , Sintomas Comportamentais/etiologia , Contagem de Células , Cromatografia Líquida de Alta Pressão , Dependovirus/genética , Modelos Animais de Doenças , Progressão da Doença , Dopamina/metabolismo , Neurônios Dopaminérgicos/patologia , Proteínas ELAV/metabolismo , Ensaio de Imunoadsorção Enzimática , Feminino , Regulação da Expressão Gênica/genética , Proteínas de Fluorescência Verde/genética , Humanos , Levodopa/farmacologia , Levodopa/uso terapêutico , Proteínas do Tecido Nervoso/metabolismo , Doenças Neurodegenerativas/etiologia , Doença de Parkinson/complicações , Doença de Parkinson/tratamento farmacológico , Doença de Parkinson/genética , Ratos , Ratos Sprague-Dawley , Elementos Reguladores de Transcrição/genética , Comportamento Estereotipado/efeitos dos fármacos , Comportamento Estereotipado/fisiologia , Fatores de Tempo , Tirosina 3-Mono-Oxigenase/metabolismo , Proteínas Vesiculares de Transporte de Monoamina/metabolismo , alfa-Sinucleína/metabolismo
15.
Blood Cancer J ; 1(7): e31, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-22829187

RESUMO

Malignant cells are known to have increased glucose uptake and accelerated glucose metabolism. Using liquid chromatography and mass spectrometry, we found that treatment of acute lymphoblastic leukemia (ALL) cells with the glucocorticoid (GC) dexamethasone (Dex) resulted in profound inhibition of glycolysis. We thus demonstrate that Dex reduced glucose consumption, glucose utilization and glucose uptake by leukemic cells. Furthermore, Dex treatment decreased the levels of the plasma membrane-associated glucose transporter GLUT1, thus revealing the mechanism for the inhibition of glucose uptake. Inhibition of glucose uptake correlated with induction of cell death in ALL cell lines and in leukemic blasts from ALL patients cultured ex vivo. Addition of di-methyl succinate could partially overcome cell death induced by Dex in RS4;11 cells, thereby further supporting the notion that inhibition of glycolysis contributes to the induction of apoptosis. Finally, Dex killed RS4;11 cells significantly more efficiently when cultured in lower glucose concentrations suggesting that modulation of glucose levels might influence the effectiveness of GC treatment in ALL. In summary, our data show that GC treatment blocks glucose uptake by leukemic cells leading to inhibition of glycolysis and that these effects play an important role in the induction of cell death by these drugs.

16.
Diabetes Obes Metab ; 11 Suppl 4: 143-8, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19817796

RESUMO

Stresses associated with the diabetic state participate in the demise of beta-cells and therapies that eliminate or reduce such stresses are much needed. K-ATP channel openers, of which diazoxide is the most studied, are potentially useful because experimental studies show that they can counteract chronic over-stimulation of beta-cells and protect against toxic conditions, including relative hypoxia. Several mechanisms may underlie the beneficial effects of diazoxide; these may include both indirect (counteracting over-stimulation) and direct mitochondrial effects. Side effects of diazoxide have limited its use in human trials. We have tested lower doses than previously of diazoxide and thereby largely eliminated side effects. In this setting, we demonstrate positive effects on beta-cell function in type 2 diabetic patients who were simultaneously treated with bedtime insulin. However, such effects were absent in insulin-naïve patients. In newly diagnosed type 1 diabetic patients, a 6-month intervention with diazoxide failed to result in better preservation of beta-cell function. K-ATP channel openers have a potential to improve beta-cell function in subgroups of type 2 diabetes patients. Analogues of diazoxide with more potency in relation to side effects would heighten the possibilities for K-ATP channel openers to be of therapeutic use in type 1 diabetes.


Assuntos
Diabetes Mellitus Tipo 1/tratamento farmacológico , Diabetes Mellitus Tipo 2/tratamento farmacológico , Diazóxido/farmacologia , Hipoglicemiantes/farmacologia , Insulina/farmacologia , Ilhotas Pancreáticas/efeitos dos fármacos , Canais KATP/efeitos dos fármacos , Diabetes Mellitus Tipo 1/metabolismo , Diabetes Mellitus Tipo 2/metabolismo , Diazóxido/administração & dosagem , Humanos , Hipoglicemiantes/administração & dosagem , Ilhotas Pancreáticas/metabolismo , Canais KATP/metabolismo
17.
J Hazard Mater ; 170(2-3): 1101-9, 2009 Oct 30.
Artigo em Inglês | MEDLINE | ID: mdl-19560864

RESUMO

The Swedish Armed Forces have large stocks of ammunition that were produced at a time when decommissioning was not considered. This ammunition will eventually become obsolete and must be destroyed, preferably with minimal impact on the environment and in a safe way for personnel. The aim of this paper is to make a comparison of the environmental impacts in a life cycle perspective of three different methods of decommissioning/destruction of ammunition, and to identify the environmental advantages and disadvantages of each of these destruction methods: open detonation; static kiln incineration with air pollution control combined with metal recycling, and a combination of incineration with air pollution control, open burning, recovery of some energetic material and metal recycling. Data used are for the specific processes and from established LCA databases. Recycling the materials in the ammunition and minimising the spread of airborne pollutants during incineration were found to be the most important factors affecting the life cycle environmental performance of the compared destruction methods. Open detonation with or without metal recycling proved to be the overall worst alternative from a life cycle perspective. The results for the static kiln and combination treatment indicate that the kind of ammunition and location of the destruction plant might determine the choice of method, since the environmental impacts from these methods are of little difference in the case of this specific grenade. Different methods for destruction of ammunition have previously been discussed from a risk and safety perspective. This is however to our knowledge the first study looking specifically on environmentally aspect in a life cycle perspective.


Assuntos
Poluição do Ar/prevenção & controle , Poluentes Ambientais/análise , Substâncias Explosivas/análise , Substâncias Perigosas/análise , Eliminação de Resíduos/métodos , Conservação dos Recursos Naturais , Explosões , Incineração , Metais/análise
18.
Cell Death Differ ; 16(7): 1018-29, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19390558

RESUMO

Glucocorticoids are fundamental drugs used in the treatment of lymphoid malignancies with apoptotic cell death as the hitherto proposed mechanism of action. Recent studies, however, showed that an alternative mode of cell death, autophagy, is involved in the response to anticancer drugs. The specific role of autophagy and its relationship to apoptosis remains, nevertheless, controversial: it can either lead to cell survival or can function in cell death. We show that dexamethasone induced autophagy upstream of apoptosis in acute lymphoblastic leukemia cells. Inhibition of autophagy by siRNA-mediated repression of Beclin 1 expression inhibited apoptosis showing an important role of autophagy in dexamethasone-induced cell death. Dexamethasone treatment caused an upregulation of promyelocytic leukemia protein, PML, its complex formation with protein kinase B or Akt and a PML-dependent Akt dephosphorylation. Initiation of autophagy and the onset of apoptosis were both dependent on these events. PML knockout thymocytes were resistant to dexamethasone-induced death and upregulation of PML correlated with the ability of dexamethasone to kill primary leukemic cells. Our data reveal key mechanisms of dexamethasone-induced cell death that may inform the development of improved treatment protocols for lymphoid malignancies.


Assuntos
Antineoplásicos Hormonais/farmacologia , Apoptose , Autofagia , Dexametasona/farmacologia , Leucemia Linfoide/metabolismo , Adolescente , Idoso , Idoso de 80 Anos ou mais , Linhagem Celular Tumoral , Cromonas/farmacologia , Inibidores Enzimáticos/farmacologia , Feminino , Humanos , Masculino , Microscopia Eletrônica de Transmissão , Proteínas Associadas aos Microtúbulos/agonistas , Proteínas Associadas aos Microtúbulos/metabolismo , Pessoa de Meia-Idade , Morfolinas/farmacologia , Proteínas Nucleares/agonistas , Proteínas Nucleares/metabolismo , Fosfatidilinositol 3-Quinases/metabolismo , Inibidores de Fosfoinositídeo-3 Quinase , Proteína da Leucemia Promielocítica , Proteínas Proto-Oncogênicas c-akt/efeitos dos fármacos , Proteínas Proto-Oncogênicas c-akt/metabolismo , Fatores de Transcrição/agonistas , Fatores de Transcrição/metabolismo , Proteínas Supressoras de Tumor/agonistas , Proteínas Supressoras de Tumor/metabolismo
19.
Mol Cell Endocrinol ; 297(1-2): 86-92, 2009 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-18621094

RESUMO

It is firmly established that poor metabolic control in diabetes inhibits beta cell function. Chronic hyperglycaemia is probably the most important factor, exerting both primary negative effects (by glucose per se and/or metabolites) and secondary ones (by beta cell exhaustion). Dyslipidemia in diabetes aggravates the glucose effects both by inducing insulin resistance and by direct effects on beta cells. Much experimental and some clinical evidence indicates that therapies that promote "beta cell rest" such as early and intensive insulin treatment and K-ATP channel blockers can be beneficial.


Assuntos
Diabetes Mellitus/fisiopatologia , Células Secretoras de Insulina/metabolismo , Células Secretoras de Insulina/patologia , Adaptação Fisiológica/efeitos dos fármacos , Animais , Sobrevivência Celular/efeitos dos fármacos , Diabetes Mellitus/terapia , Glucose/toxicidade , Humanos , Células Secretoras de Insulina/efeitos dos fármacos , Lipídeos/toxicidade
20.
J Nutr Health Aging ; 12(3): 176-82, 2008 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18309437

RESUMO

OBJECTIVES: To analyse, describe and compare the frequency and energy intake of eating events, including specific food items, among diseased older men living in ordinary housing. DESIGN: Descriptive and explorative. SETTING: Interviews were performed in the participants' home. PARTICIPANTS: Thirty-five co-living and 26 single-living men, 64-88 years of age. Participants had one of three chronic diseases associated with difficulties in buying and preparing food and with difficulties related to the meal situation: Parkinson's disease, rheumatoid arthritis or stroke. MEASUREMENTS: A repeated 24-h recall was used to assess food intake and meal patterns. RESULTS: Eating events were distributed over a 24-h period. Co-living men had a higher (p=0.001) number of eating events/day; both hot and cold eating events were consumed more frequently. There was no difference between groups concerning energy intake. Co-living men more often had hot eating events cooked from raw ingredients (p=0.001) and a greater mix of vegetables/roots (p=0.003) included in such eating events. CONCLUSION: Single-living men may constitute a vulnerable group from a nutritional perspective, while co-living men, besides the pleasure of eating with another person, seem to get support with food and eating events from their partners. Hence, the group of single-living men, particularly those with a disability, should receive particular attention with regard to possible food-related difficulties.


Assuntos
Artrite Reumatoide , Dieta/estatística & dados numéricos , Comportamento Alimentar , Doença de Parkinson , Pessoa Solteira , Acidente Vascular Cerebral , Idoso , Idoso de 80 Anos ou mais , Culinária , Ingestão de Energia , Humanos , Entrevistas como Assunto , Masculino , Rememoração Mental , Pessoa de Meia-Idade , Suécia/epidemiologia , Verduras
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...